Home » NEXMED RELEASES RESULTS OF PHASE I FUNGUS STUDY
NEXMED RELEASES RESULTS OF PHASE I FUNGUS STUDY
NexMed has reported that an early study showed its topical nail fungus treatment
left substantially less drug in the bloodstream than the leading oral medicine,
potentially making it a safer therapy.
The company's experimental NM100060 treatment uses a proprietary technology
to boost the skin's drug absorption. It contains less than 1 percent of the
oral dose of terbinafine, the active ingredient in Novartis AG's Lamisil tablet.
The NexMed drug showed peak blood plasma levels about 2,500 times less than
those of a single Lamisil tablet, and were comparable with the blood levels
of an athlete's foot cream using the same active ingredient.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May